참고문헌
- Azzoli CG, Baker Jr S, Temin S, et al (2009). American society of clinical oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol, 27, 6251-66. https://doi.org/10.1200/JCO.2009.23.5622
- Boyle P, Ferlay J (2004). Cancer incidence and mortality in Europe. Ann Oncol, 16, 481-8.
- Ciuleanu T, Stelmakh L, Clicenas S, et al(2012). Efficacy and safety of erlotinib versus chemotherapy in secondline treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol, 13, 300-8. https://doi.org/10.1016/S1470-2045(11)70385-0
- Di Maio M, Lama N, Morabito A, et al (2010). Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: a prognostic score from individual data of nine randomised trials. Eur J Cancer, 46, 735-43 https://doi.org/10.1016/j.ejca.2009.12.013
- Di Maio M, Krzakowski M, Fougeray R, Kowalski DM, Gridelli C (2012). Prognostic score for second-line chemotherapy of advanced non-small-cell lung cancer: External validation in a phase III trial comparing vinflunine with docetaxel. Lung Cancer, Feb 21
- Hanna N, Shepherd FA, Fossella FV, et al (2004). Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol, 22, 1589-97. https://doi.org/10.1200/JCO.2004.08.163
- Hotta K, Fujiwara Y, Kiura K, et al (2007). Relationship between response and survival in more than 50,000 patients with advanced non-small cell lung cancer treated with systemic chemotherapy in 143 phase III trials. J Thoracic Oncol, 2, 402-7. https://doi.org/10.1097/01.JTO.0000268673.95119.c7
- Kim JG, Ryoo BY, Park YH, et al (2008). Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy. Cancer Chemother Pharmacol, 61, 301-7.
- Krishnan S, Rana V, Janjan NA, et al (2006). Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation. Cancer, 107, 2589-96. https://doi.org/10.1002/cncr.22328
- Mitry E, Douillard JY, Van Cutsem E, et al (2004). Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trial. Ann Oncol, 15, 1013-7. https://doi.org/10.1093/annonc/mdh267
- Scartozzi M, Mazzanti P, Giampieri R, et al (2010). Clinical predictive factors for advanced non-small cell lung cancer (NSCLC) patients receiving third-line therapy: selecting the unselectable? Lung Cancer, 68, 433-7. https://doi.org/10.1016/j.lungcan.2009.07.008
- Schiller JH, Harrington D, Belani CP, et al (2002). Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med, 346, 92-8. https://doi.org/10.1056/NEJMoa011954
- Shepherd FA (1993). Screening, diagnosis, and staging of lung cancer. Curr Opin Oncol, 5, 310-22. https://doi.org/10.1097/00001622-199303000-00010
- Wataya H, Okamoto T, Maruyama R, et al (2009). Prognostic factors in previously treated non-small cell lung cancer patients with and without a positive response to the subsequent treatment with gefitinib. Lung Cancer, 64, 341-5. https://doi.org/10.1016/j.lungcan.2008.09.005
- Weiss GJ, Rosell R, Fossella F, et al (2007). The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer. Ann Oncol, 18, 453-60.
- Zietemann V, Duell T (2011). Prevalence and effectiveness of first-, second-, and third-line systemic therpy in a cohort of unselected patients with advanced non-small cell lung cancer. Lung Cancer, 73, 70-7. https://doi.org/10.1016/j.lungcan.2010.10.017
피인용 문헌
- Analysis of prognostic factors for overall survival in patients with advanced non-small cell lung cancer treated with second line chemotherapy vol.02, pp.03, 2013, https://doi.org/10.4236/alc.2013.23007
- Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Versus Placebo as Maintenance Therapy for Advanced Non-small-cell Lung Cancer: A Meta-analysis of Randomized Controlled Trials vol.14, pp.4, 2013, https://doi.org/10.7314/APJCP.2013.14.4.2413
- Differences in Epidermal Growth Factor Receptor Gene Mutations and Relationship with Clinicopathological Features in NSCLC Between Uygur and Han Ethnic Groups vol.14, pp.5, 2013, https://doi.org/10.7314/APJCP.2013.14.5.2879
- Efficacy of First-line Chemotherapy Affects the Second-Line Setting Response in Patients with Advanced Non-Small Cell Lung Cancer vol.15, pp.16, 2014, https://doi.org/10.7314/APJCP.2014.15.16.6799
- Edition Staging System vol.15, pp.6, 2014, https://doi.org/10.7314/APJCP.2014.15.6.2465
- Outcomes of Second-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer in One Institution vol.77, pp.1, 2014, https://doi.org/10.4046/trd.2014.77.1.13